Patents by Inventor John S. Lollar
John S. Lollar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170119857Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: ApplicationFiled: June 10, 2016Publication date: May 4, 2017Applicants: Emory University, Baxalta GmbH, Baxalta IncorporatedInventors: John S. LOLLAR, Garrett E. BERGMAN
-
Publication number: 20160030529Abstract: This disclosure relates to composition and methods for improving blood clotting in a subject that developed anti-factor VIII antibodies. In certain embodiments, this disclosure contemplates a conjugate comprising a toxin, e.g., ricin, abrin, saporin, coupled to factor VIII or functional variant thereof either through a linking group or as a fusion protein.Type: ApplicationFiled: March 13, 2014Publication date: February 4, 2016Inventors: John S LOLLAR, John F HEALEY
-
Publication number: 20150352190Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.Type: ApplicationFiled: January 27, 2015Publication date: December 10, 2015Applicant: Emory UniversityInventor: John S. Lollar
-
Patent number: 8951515Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.Type: GrantFiled: March 27, 2012Date of Patent: February 10, 2015Assignee: Emory UniversityInventor: John S. Lollar
-
Publication number: 20140193441Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: ApplicationFiled: August 5, 2013Publication date: July 10, 2014Inventors: John S. Lollar, Garrett E. Bergman
-
Patent number: 8519111Abstract: Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A.Type: GrantFiled: May 27, 2012Date of Patent: August 27, 2013Assignee: Expression Therapeutics LLCInventor: John S Lollar
-
Patent number: 8501694Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: GrantFiled: January 23, 2012Date of Patent: August 6, 2013Assignees: Emory University, Baxter International Inc., Baxter Healthcare SAInventors: John S. Lollar, Garrett E. Bergman
-
Publication number: 20130005656Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.Type: ApplicationFiled: March 27, 2012Publication date: January 3, 2013Applicant: Emory UniversityInventor: John S. Lollar
-
Publication number: 20120270266Abstract: Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A.Type: ApplicationFiled: May 27, 2012Publication date: October 25, 2012Inventor: John S. Lollar
-
Publication number: 20120270788Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: ApplicationFiled: January 23, 2012Publication date: October 25, 2012Applicant: Emory UniversityInventors: John S. Lollar, Garrett E. Bergman
-
Patent number: 8188246Abstract: Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A.Type: GrantFiled: December 11, 2009Date of Patent: May 29, 2012Assignee: Expression Therapeutics LLCInventor: John S. Lollar
-
Patent number: 8101718Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: GrantFiled: July 1, 2009Date of Patent: January 24, 2012Assignees: Emory University, Ipsen Biopharm LimitedInventors: John S Lollar, Garrett E. Bergman
-
Publication number: 20110077203Abstract: Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A.Type: ApplicationFiled: December 11, 2009Publication date: March 31, 2011Inventor: John S. Lollar
-
Publication number: 20090325881Abstract: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.Type: ApplicationFiled: June 25, 2009Publication date: December 31, 2009Applicant: Emory UniversityInventor: John S. Lollar
-
Patent number: 7635763Abstract: Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A.Type: GrantFiled: March 30, 2004Date of Patent: December 22, 2009Assignee: Expression Therapeutics, LLC.Inventor: John S. Lollar
-
Publication number: 20090270329Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: ApplicationFiled: July 1, 2009Publication date: October 29, 2009Applicant: Emory UniversityInventors: John S. Lollar, Garrett E. Bergman
-
Patent number: 7576181Abstract: The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency.Type: GrantFiled: October 12, 2006Date of Patent: August 18, 2009Assignees: IPSEN Biopharm Limited, Emory UniversityInventors: John S. Lollar, Garrett E. Bergman
-
Patent number: 7560107Abstract: Modified porcine factor VIII is disclosed in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes.Type: GrantFiled: October 17, 2006Date of Patent: July 14, 2009Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 7122634Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.Type: GrantFiled: September 10, 2004Date of Patent: October 17, 2006Assignee: Emory UniversityInventor: John S. Lollar
-
Patent number: 7033791Abstract: Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the A2 domain. The modified factor VIII is useful as a clotting factor supplement for hemophiliacs.Type: GrantFiled: April 23, 2002Date of Patent: April 25, 2006Assignee: Emory UniversityInventor: John S. Lollar